Valeant Pharmaceuticals International, Inc. (NYSE:VRX) went lower by -0.64% to close at $ 20.14. The company exchanged total volume of 14.14 million shares throughout course of last trade however it holds an average trading capacity of 32.63 million shares. Shares of company began trading at $20.01 climbed to high of $20.46 touched the low of $19.45.
The company is trading below its 50-day moving averages of 25.05 and down from 200-day moving averages of 56.23. The firm has price to book ratio of 1.23 and its price to sale ratio was 0.65.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:VRX) reported that its associate and AstraZeneca (LSE/SSE/NYSE: AZN) have amended Valeant’s license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant’s right to develop and commercialize brodalumab in Europe.
In August 2015, AstraZeneca and Valeant entered into an contract granting Valeant an exclusive license to develop and commercialize brodalumab globally, other than in Japan and certain other Asian countries. Under the terms of the amended contract, Valeant will continue to hold the license to develop and commercialize brodalumab in the U.S, as well as the remainder of the territory outside of Europe.
Valeant Pharmaceuticals International, Inc.’s (VRX) has price-to-cash ratio of 5.25 and price to sale ratio of 0.65. The company net profit margin is -7.00% and gross profit margin is 75.20%. A look on the firm performance, its monthly performance is -32.39% and a quarterly performance of -28.33%. The stock price is moving down from its 20 days moving average with -14.05% and isolated negatively from 50 days moving average with -26.92%.
Depomed, Inc. (NASDAQ:DEPO) surged +1.03% and closed the trade at $ 19.62. The company recorded a trading capacity of 1.91 million shares above its three months average daily volume of 1.8 million shares. During the last trade, shares reached to high price of $19.66 and touched the low price of $18.53. The stock’s 50-day moving average is noted at $19.57 and its 200-day moving average is stands at $17.02.
Additionally, the company has EPS of -1.41. The company has market capitalization of $1.20B.
The average true range of Depomed, Inc.’s (DEPO) is recorded at 0.85 and the relative strength index of the stock stands 53.50. The stock price is going above to its 52 week low with 60.16% and lagging behind from its 52 week high with -41.85%. Analyst recommendation for this stock stands at 2.00. A look on the firm performance, its monthly performance is -5.31% and a quarterly performance of 36.44%. The stock price is trading upbeat from its 200 days moving average with 9.74% and up from 50 days moving average with 3.98%.